~~<i id='3DC8F09372'><strike id='3DC8F09372'><tt id='3DC8F09372'><pre id='3DC8F09372'></pre></tt></strike></i>~~

Home» focus» Wikipedia

Wikipedia

author：comprehensive 2025-09-28 00:57:13 Page View：289

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： White House drug shortages task force keeps mum with Congress
Next article： As demand for Covid shots wanes, Moderna seeks its next success

explore

After affirmative action ruling, medical educators look to 'holistic review'

AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

Timeline: Key moments in fight for gay rights

1:12VIDEO:TheFightforGayRightsinAmericaKeystone/HultonArchive/GettyImages,FILEJunemarksPrideMonthfor

Wildfire smoke exposes gaps in outdoor worker protections

ApersonwaitingforthesubwaywearsafilteredmaskassmokyhazefromwildfiresinCanadablanketsaneighborhoodinN

CDC overhauls leadership of center that led response to Covid

DemetreDaskalakis,whohasspentthepastyearinWashingtonasdeputydirectoroftheWhiteHouse’smpoxresponse,wa